Aaron E Miller

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Glatiramer acetate in the treatment of multiple sclerosis
    Aaron E Miller
    Department of Neurology, Mt Sinai School of Medicine, New York, NY, USA
    Neurol Clin 23:215-31, viii. 2005
  2. doi request reprint Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    Clin Ther 37:2366-80. 2015
  3. doi request reprint Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, New York, NY, USA Electronic address
    Lancet Neurol 13:977-86. 2014
  4. pmc Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY, 10028, USA
    J Neurol 261:1781-8. 2014
  5. pmc Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
    Aaron E Miller
    Mount Sinai School of Medicine, USA
    Mult Scler 18:1625-32. 2012
  6. doi request reprint Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs
    Aaron E Miller
    Corinne Goldsmith Dikinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, New York 10029, USA
    Curr Opin Neurol 25:S4-10. 2012
  7. doi request reprint Multiple sclerosis: where will we be in 2020?
    Aaron E Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 78:268-79. 2011
  8. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008
  9. ncbi request reprint Immunotherapy of multiple sclerosis--current practice and future directions
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    J Rehabil Res Dev 39:273-85. 2002
  10. ncbi request reprint Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial
    Jerry S Wolinsky
    Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Ann Neurol 61:14-24. 2007

Detail Information

Publications13

  1. ncbi request reprint Glatiramer acetate in the treatment of multiple sclerosis
    Aaron E Miller
    Department of Neurology, Mt Sinai School of Medicine, New York, NY, USA
    Neurol Clin 23:215-31, viii. 2005
  2. doi request reprint Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    Clin Ther 37:2366-80. 2015
    ..The purpose was to summarize US prescribing information for teriflunomide in the treatment of patients with relapsing forms of multiple sclerosis (RMS), with reference to clinical efficacy and safety outcomes...
  3. doi request reprint Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, New York, NY, USA Electronic address
    Lancet Neurol 13:977-86. 2014
    ..We aimed to assess the efficacy and safety of teriflunomide in patients with a first clinical episode suggestive of multiple sclerosis...
  4. pmc Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
    Aaron E Miller
    Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY, 10028, USA
    J Neurol 261:1781-8. 2014
    ..009) and had lower annualized rates of all hospitalizations (p = 0.030). Taken together, the positive effects of teriflunomide on severe relapses indicate that teriflunomide may reduce relapse-related healthcare costs. ..
  5. pmc Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
    Aaron E Miller
    Mount Sinai School of Medicine, USA
    Mult Scler 18:1625-32. 2012
    ....
  6. doi request reprint Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs
    Aaron E Miller
    Corinne Goldsmith Dikinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, New York 10029, USA
    Curr Opin Neurol 25:S4-10. 2012
    ....
  7. doi request reprint Multiple sclerosis: where will we be in 2020?
    Aaron E Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 78:268-79. 2011
    ..This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade...
  8. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008
    ..0 reached EDSS >or= 6.0. Adverse events were similar to those reported in short-term clinical trials. This study shows a low rate of relapses and EDSS progression in RRMS patients on GA for up to 22 years...
  9. ncbi request reprint Immunotherapy of multiple sclerosis--current practice and future directions
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    J Rehabil Res Dev 39:273-85. 2002
    ..Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure...
  10. ncbi request reprint Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial
    Jerry S Wolinsky
    Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Ann Neurol 61:14-24. 2007
    ..To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis...
  11. pmc Defining the clinical course of multiple sclerosis: the 2013 revisions
    Fred D Lublin
    From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis F D L, A E M, Icahn School of Medicine at Mount Sinai, New York, NY Scientific and Clinical Review Associates, LLC S C R, Salisbury, CT The Mellen Center for MS Treatment and Research J A C, R J F, R A R, Cleveland Clinic, OH the Department of Biostatistics G R C, University of Alabama at Birmingham the Danish Multiple Sclerosis Center P S S, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark University College London Institute of Neurology A J T, UK the Department of Neurology J S W, J A L, University of Texas Health Sciences Center, Houston the Department of Neurology L J B, New York University Langone Medical Center, New York the Division of Neurology B Banwell, The Children s Hospital of Philadelphia, PA the Departments of Radiology and Nuclear Medicine F B and Neurology C H P, VU Medical Center, Amsterdam, the Netherlands Research Programs Department B Bebo, National Multiple Sclerosis Society, New York, NY the Department of Neurology P A C, The Johns Hopkins Hospital, Baltimore, MD Fédération de Neurologie M C, CHU Hôpital Purpan, Toulouse, France the Department of Neurology G C, Scientific Institute San Raffaele, Department of Pediatrics
    Neurology 83:278-86. 2014
    ..Strategies for future research to better define phenotypes are also outlined. ..
  12. doi request reprint Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  13. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...